tiprankstipranks
Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
US Market
KLRS
Kalaris Therapeutics
RESEARCH TOOLSreports
Want to see KLRS full AI Analyst Report?

Kalaris Therapeutics (KLRS) Stock Forecast & Price Target

375 Followers
See the Price Targets and Ratings of:

KLRS Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Kalaris
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KLRS Stock 12 Month Forecast

Average Price Target

$15.75
▲(149.21% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Kalaris Therapeutics in the last 3 months. The average price target is $15.75 with a high forecast of $25.00 and a low forecast of $7.00. The average price target represents a 149.21% change from the last price of $6.32.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.46,6.9630769230769225,8.466153846153846,9.96923076923077,11.472307692307691,12.975384615384616,14.478461538461538,15.98153846153846,17.484615384615385,18.987692307692306,20.49076923076923,21.993846153846153,23.496923076923075,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.46,6.251538461538462,7.043076923076923,7.834615384615384,8.626153846153846,9.417692307692308,10.209230769230768,11.00076923076923,11.792307692307691,12.583846153846153,13.375384615384615,14.166923076923077,14.958461538461538,{"y":15.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.46,5.578461538461538,5.696923076923077,5.815384615384615,5.9338461538461535,6.052307692307692,6.170769230769231,6.28923076923077,6.407692307692308,6.526153846153846,6.644615384615385,6.763076923076923,6.881538461538462,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.44,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.935,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.46,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$15.75Lowest Price Target$7.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on KLRS
Yun Zhong
Wedbush
Wedbush
$17
Buy
168.99%
Upside
Initiated
05/14/26
Kalaris Therapeutics initiated with an Outperform at WedbushKalaris Therapeutics initiated with an Outperform at Wedbush
Citizens JMP Analyst forecast on KLRS
Jonathan Wolleben
Citizens JMP
Citizens JMP
$26→$25
Buy
295.57%
Upside
Reiterated
05/13/26
Kalaris Therapeutics price target lowered to $25 from $26 at CitizensKalaris Therapeutics price target lowered to $25 from $26 at Citizens
Morgan Stanley Analyst forecast on KLRS
Judah Frommer
Morgan Stanley
Morgan Stanley
$14
Buy
121.52%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Kalaris Therapeutics (NASDAQ: KLRS), Zentalis Pharmaceuticals (NASDAQ: ZNTL) and Bristol-Myers Squibb (NYSE: BMY)
William Blair Analyst forecast on KLRS
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
05/12/26
Analysts Are Bullish on Top Healthcare Stocks: Immunome (IMNM), Kalaris Therapeutics (KLRS)
Piper Sandler Analyst forecast on KLRS
Biren Amin
Piper Sandler
Piper Sandler
$7
Hold
10.76%
Upside
Reiterated
03/30/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Chardan Capital Analyst forecast on KLRS
Daniil Gataulin
Chardan Capital
Chardan Capital
$19
Buy
200.63%
Upside
Initiated
12/23/25
Kalaris Therapeutics (KLRS) Initiated with a Buy at Chardan Capital
Leerink Partners Analyst forecast on KLRS
Marc Goodman
Leerink Partners
Leerink Partners
$20
Buy
216.46%
Upside
Reiterated
09/16/25
Leerink Partners Remains a Buy on Kalaris Therapeutics (KLRS)
Raymond James Analyst forecast on KLRS
Christopher Raymond
Raymond James
Raymond James
$23
Buy
263.92%
Upside
Reiterated
09/16/25
Kalaris Therapeutics (KLRS) Receives a Buy from Raymond James
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on KLRS
Yun Zhong
Wedbush
Wedbush
$17
Buy
168.99%
Upside
Initiated
05/14/26
Kalaris Therapeutics initiated with an Outperform at WedbushKalaris Therapeutics initiated with an Outperform at Wedbush
Citizens JMP Analyst forecast on KLRS
Jonathan Wolleben
Citizens JMP
Citizens JMP
$26→$25
Buy
295.57%
Upside
Reiterated
05/13/26
Kalaris Therapeutics price target lowered to $25 from $26 at CitizensKalaris Therapeutics price target lowered to $25 from $26 at Citizens
Morgan Stanley Analyst forecast on KLRS
Judah Frommer
Morgan Stanley
Morgan Stanley
$14
Buy
121.52%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Kalaris Therapeutics (NASDAQ: KLRS), Zentalis Pharmaceuticals (NASDAQ: ZNTL) and Bristol-Myers Squibb (NYSE: BMY)
William Blair Analyst forecast on KLRS
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
05/12/26
Analysts Are Bullish on Top Healthcare Stocks: Immunome (IMNM), Kalaris Therapeutics (KLRS)
Piper Sandler Analyst forecast on KLRS
Biren Amin
Piper Sandler
Piper Sandler
$7
Hold
10.76%
Upside
Reiterated
03/30/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Chardan Capital Analyst forecast on KLRS
Daniil Gataulin
Chardan Capital
Chardan Capital
$19
Buy
200.63%
Upside
Initiated
12/23/25
Kalaris Therapeutics (KLRS) Initiated with a Buy at Chardan Capital
Leerink Partners Analyst forecast on KLRS
Marc Goodman
Leerink Partners
Leerink Partners
$20
Buy
216.46%
Upside
Reiterated
09/16/25
Leerink Partners Remains a Buy on Kalaris Therapeutics (KLRS)
Raymond James Analyst forecast on KLRS
Christopher Raymond
Raymond James
Raymond James
$23
Buy
263.92%
Upside
Reiterated
09/16/25
Kalaris Therapeutics (KLRS) Receives a Buy from Raymond James
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kalaris Therapeutics

3 Months
Lachlan Hanbury BrownWilliam Blair
Success Rate
6/10 ratings generated profit
60%
Average Return
+35.16%
Copying Lachlan Hanbury Brown's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +35.16% per trade.
1 Year
Lachlan Hanbury BrownWilliam Blair
Success Rate
7/10 ratings generated profit
70%
Average Return
+25.03%
Copying Lachlan Hanbury Brown's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +25.03% per trade.
2 Years
Lachlan Hanbury BrownWilliam Blair
Success Rate
7/10 ratings generated profit
70%
Average Return
+23.45%
Copying Lachlan Hanbury Brown's trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +23.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KLRS Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
3
2
0
1
4
Buy
2
1
2
2
3
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
4
3
4
8
In the current month, KLRS has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KLRS average Analyst price target in the past 3 months is 15.75.
Each month's total comprises the sum of three months' worth of ratings.

KLRS Financial Forecast

KLRS Earnings Forecast

Next quarter’s earnings estimate for KLRS is -$0.47 with a range of -$0.53 to -$0.30. The previous quarter’s EPS was -$0.46. KLRS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year KLRS has Performed in-line its overall industry.
Next quarter’s earnings estimate for KLRS is -$0.47 with a range of -$0.53 to -$0.30. The previous quarter’s EPS was -$0.46. KLRS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year KLRS has Performed in-line its overall industry.
No data currently available

KLRS Sales Forecast

Next quarter’s sales forecast for KLRS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KLRS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year KLRS has Performed in-line its overall industry.
Next quarter’s sales forecast for KLRS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KLRS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year KLRS has Performed in-line its overall industry.

KLRS Stock Forecast FAQ

What is KLRS’s average 12-month price target, according to analysts?
Based on analyst ratings, Kalaris Therapeutics’s 12-month average price target is 15.75.
    What is KLRS’s upside potential, based on the analysts’ average price target?
    Kalaris Therapeutics has 149.21% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KLRS a Buy, Sell or Hold?
          Kalaris Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Kalaris Therapeutics’s price target?
            The average price target for Kalaris Therapeutics is 15.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $7.00. The average price target represents 149.21% Increase from the current price of $6.32.
              What do analysts say about Kalaris Therapeutics?
              Kalaris Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of KLRS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.